Focused On-demand Library for Tripartite motif-containing protein 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

RING finger protein 89; RING-type E3 ubiquitin transferase TRIM6

Alternative UPACC:

Q9C030; A8K2A7; B4DDQ5; Q86WZ8; Q9HCR1


Tripartite motif-containing protein 6 (TRIM6), also known as RING finger protein 89, is a pivotal E3 ubiquitin ligase. It orchestrates the activation of the IKBKE-dependent branch of the type I interferon signaling pathway, crucial for antiviral responses. TRIM6, in collaboration with UBE2K, generates 'Lys-48'-linked polyubiquitin chains, facilitating IKBKE oligomerization and autophosphorylation. Additionally, it ubiquitinates MYC, regulating embryonic stem cell pluripotency, and enhances RIGI-mediated antiviral immune responses by promoting 'Lys-48'-polyubiquitin chain association with DHX16.

Therapeutic significance:

Understanding the role of Tripartite motif-containing protein 6 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.